De­spite Phase 3 win, Roche says rare au­toim­mune drug did­n't meet ex­pec­ta­tions

Roche’s Chugai Phar­ma­ceu­ti­cal said its im­mune dis­ease drug En­spryng didn’t pro­duce the re­sults it was hop­ing for in a Phase 3 study in gen­er­al­ized myas­the­nia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER